Fletcher Courtney V
Clinical Pharmacy and Infectious Diseases, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA.
Drugs. 2007;67(14):1969-79. doi: 10.2165/00003495-200767140-00001.
Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The frequency and number of medications (conventionally referred to as the pill count) contribute to regimen effectiveness. However, clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Potency and durability, the potential for drug-drug interactions, and the occurrence of adverse events also contribute to the effectiveness and complexity of a drug regimen. A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV.
正如最近几项抗逆转录病毒（ARV）疗法的临床试验所表明的那样，可以实现对HIV复制的持久和持续抑制。然而，在实验环境中所证明的疗效并不总是能转化为临床环境中的实际效果。药物的服用频率和数量（传统上称为药片数量）会影响治疗方案的效果。然而，临床医生和感染HIV的患者认识到，ARV治疗方案还有其他几个特征，它们对治疗方案的效果同样起着重要作用。药物的效力和持久性、药物相互作用的可能性以及不良事件的发生也会影响药物治疗方案的效果和复杂性。全面考虑与疗效相关的因素将优化针对个体HIV感染者的疗效转化为实际效果。
